XLO trades 109.7% below Wall Street's consensus target of $16.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes XLO achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 19, 2026, Xilio Therapeutics, Inc. (XLO) has a Wall Street consensus price target of $16.00, based on estimates from 3 covering analysts. With the stock currently trading at $7.63, this represents a potential upside of +109.7%. The company has a market capitalization of $50M.
Analyst price targets range from a low of $16.00 to a high of $16.00, representing a 0% spread in expectations. The median target of $16.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, XLO trades at a trailing P/E of -13.1x. Analysts expect EPS to grow -393.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NKTXNkarta, Inc. | $82M | $1.15 | $9.00 | +682.6% | Buy | — | 12 |
IMVTImmunovant, Inc. | $6.8B | $33.17 | $40.00 | +20.6% | Buy | — | 23 |
RCUSArcus Biosciences, Inc. | $2.0B | $15.76 | $40.67 | +158.1% | Buy | — | 18 |
AGENAgenus Inc. | $267M | $6.40 | $25.00 | +290.6% | Buy | 23.9x | 12 |
CLDXCelldex Therapeutics, Inc. | $1.8B | $27.55 | $66.80 | +142.5% | Buy | — | 20 |
TGTXTG Therapeutics, Inc. | $10.1B | $66.12 | $80.50 | +21.7% | Buy | 66.1x | 13 |
ALKSAlkermes plc | $7.9B | $46.85 | $58.70 | +25.3% | Buy | — | 29 |
KYMRKymera Therapeutics, Inc. | $10.0B | $121.13 | $141.53 | +16.8% | Buy | — | 27 |
REGNRegeneron Pharmaceuticals, Inc. | $97.4B | $945.53 | $904.60 | -4.3% | Buy | 13.9x | 49 |
BMYBristol-Myers Squibb Company | $121.6B | $59.56 | $66.08 | +10.9% | Hold | 9.2x | 42 |
Quick answers to the most common questions about buying XLO stock.
The consensus Wall Street price target for XLO is $16, representing 109.7% upside from the current price of $7.63. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
XLO has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $16 implies 109.7% upside from current levels.
XLO's current price is $7.63 with a consensus target of $16 (109.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $16 for XLO, while the most conservative target is $16. The consensus of $16 represents the median expectation. These targets typically reflect 12-month expectations.
XLO is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month XLO stock forecast based on 3 Wall Street analysts shows a consensus price target of $16, with estimates ranging from $16 (bear case) to $16 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on XLO, with a "Buy" consensus rating and $16 price target (109.7% upside). 3 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
XLO analyst price targets range from $16 to $16, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $16 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.